About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Roberto Piñeiro, leads the Tumor dissemination and Circulating Tumor Cells (CTC) Laboratory, Translational Medical Oncology Group, at the Health Research Institute of Santiago de Compostela (IDIS).
Abstract: Metastatic dissemination remains the major cause of mortality in breast cancer, yet the cellular and molecular mechanisms underlying tumor cell survival and dissemination through the bloodstream remain incompletely understood. Liquid biopsy provides a unique opportunity to study these processes directly in patients and to characterize tumor cell populations relevant to metastatic progression. Our research focuses on circulating tumor cells (CTCs), particularly CTC-clusters, as both clinically relevant biomarkers and potential mediators of metastasis.We have investigated the clinical relevance of CTC and CTC-cluster enumeration in breast cancer, demonstrating their association with disease progression and patient outcome. Building on these observations, we have explored the biological properties of CTC clusters and their interactions with the tumor microenvironment, including their functional communication with cancer-associated fibroblasts using experimental models of tumor dissemination, such as zebrafish. These studies support the concept that CTC clusters are not simply aggregates of circulating tumor cells but represent a distinct population with specific biological properties that may facilitate metastatic spread.More recently, we have applied single-cell genomic approaches to investigate the molecular heterogeneity of CTCs and CTC clusters and identify features associated with aggressive phenotypes. Ongoing work is further exploring candidate regulators of CTC biology and tumor-microenvironment interactions, with the aim of understanding molecular programs underlying metastatic dissemination. Together, these studies integrate clinical liquid biopsy, functional modelling and single-cell molecular profiling to advance our understanding of CTC biology and identify molecular features with potential relevance for liquid biopsy-based biomarkers and therapeutic strategies in metastatic breast cancer.
Host: Dr. Stefan Hümmer, main researcher. Translational Molecular Pathology (VHIR)
